Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients

Blood

Volumn 115, Issue 16, 2010, Pages 3413-3414

  Kröger, Nicolaus ^a   Asenova, Svetlana ^a   Gerritzen, Andreas ^b   Bacher, Ulrike ^a   Zander, Axel ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Medizinisches Labor Bremen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; PARAPROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOASSAY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; COMPARATIVE STUDY; FOLLOW UP; HUMAN; LETTER; LIGHT CHAIN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUALITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; URINE LEVEL;

EID: 77951494547     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261677     Document Type: Letter

References (9)

1. Fernandez de Larrera C, Cibeira MT, Elena M, et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood. 2009;114(24):4954-4956.
2. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489-491.
3. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
4. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-224.
5. Mösbauer U, Ayuk F, Schieder H, et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica. 2007;92(2):275-276.
6. Blade J, Samson D, Reece D, et al. Criteria for evaluation disease response and progrssion in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123.
7. Mateo G, Montalbán MA, Vidriales MB, et al. PETHEMA Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with highdose therapy. J Clin Oncol. 2008;26(16):2737-2744.
8. Corradini P, Cavo M, Lokhorst H, et al, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102(5):1927-1929.
9. Kröger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37(7):791-798.